ST. JOSEPH, Mich., Jan. 19 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the University of Maryland School of Nursing has licensed its pathway analysis and knowledge mining suite MetaCore. The latest version, MetaCore 6.0 includes a new easy to use interface, with unique interactome analysis tools, simple searching of GeneGo's high quality manually curated content and direct links from the drug detail pages to Sigma Aldrich for purchasing compounds.
"We prefer the coverage and quality of disease annotation, as well as the rodent specific pathway analysis, which is critical to seeing species differences. I am not aware of another platform that has this capability," said Susan Dorsey, Director, UMB Center for Pain Studies.
"We are always told that we have the broadest and deepest coverage of content in the systems biology pathway area with the highest quality manual curation," said Julie Bryant, VP of Business Development. "As we focus on building our disease platforms our depth of coverage will continue to grow and provide more levels of granularity for our users on diseases, processes and toxicology."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0™, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
SOURCE GeneGo, Inc.
Advertisement
"We prefer the coverage and quality of disease annotation, as well as the rodent specific pathway analysis, which is critical to seeing species differences. I am not aware of another platform that has this capability," said Susan Dorsey, Director, UMB Center for Pain Studies.
Advertisement
"We are always told that we have the broadest and deepest coverage of content in the systems biology pathway area with the highest quality manual curation," said Julie Bryant, VP of Business Development. "As we focus on building our disease platforms our depth of coverage will continue to grow and provide more levels of granularity for our users on diseases, processes and toxicology."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0™, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
SOURCE GeneGo, Inc.
